Clik here to view.
Cognate Completes Management Buyout and Raises Growth Capital to Fund...
BALTIMORE & MEMPHIS, Tenn. Cognate BioServices, a leading contract development and manufacturing organization (“CDMO”) in the global cellular therapies industry, announced today it has completed...
View ArticleClik here to view.
武田宣布其获2018全球杰出雇主认证
日本大阪 (美国商业资讯)–武田药品工业株式会社(Takeda Pharmaceutical Company Limited, TOKYO: 4502)（ “武田”）今天宣布获评2018全球杰出雇主(Top Employer®)，该称号全球仅13家公司获得，其中药品公司仅两家。杰出雇主调研机构(Top Employers...
View ArticleClik here to view.
Maxinovel Pharmaceuticals Announces the Presentation of Its Orally Active...
GUANGZHOU, China Maxinovel Pharmaceuticals today announces that it will present preclinical results of its orally active PD-1/PD-L1 inhibitors as a single agent or combination with Epacadostat,...
View ArticleClik here to view.
Exelixis Announces Collaborator Daiichi Sankyo’s Submission of Regulatory...
SOUTH SAN FRANCISCO, Calif. Exelixis, Inc. (NASDAQ: EXEL) today announced that its partner Daiichi Sankyo Company, Limited (“Daiichi Sankyo”) has submitted its regulatory application for esaxerenone...
View ArticleClik here to view.
EpimAb Biotherapeutics Appoints Industry Veteran Bin Peng as Chief Medical...
SHANGHAI EpimAb Biotherapeutics, a biologics company based in Shanghai, China, specialized in developing a portfolio of bispecific antibodies, announced today that Bin Peng, MD, PhD, has joined the...
View ArticleClik here to view.
Cullgen Announces Series Seed Financing
TOKYO Cullgen Inc. announced a Series Seed Financing of up to $15M by GNI Group Ltd. (GNIG) (TOKYO: 2160) to build a new drug discovery platform based on advanced ubiquitin-mediated protein...
View ArticleClik here to view.
Chi-Med Initiates a Phase Ib/II Proof-of-Concept Trial of Epitinib in...
LONDON Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) has initiated a Phase Ib/II proof-of-concept study of epitinib in glioblastoma patients with epidermal growth factor receptor...
View ArticleClik here to view.
Second Sight Medical Products, Inc. to Present at the B. Riley & Co. China...
SYLMAR, Calif. Second Sight Medical Products, Inc. (NASDAQ: EYES) (“Second Sight” or “the Company”), a developer, manufacturer and marketer of implantable visual prosthetics that are intended to...
View ArticleClik here to view.
Tokai-Denshi Developed A.I.-Equipped Portable Odor Detector/Identifier...
FUJI, Japan Tokai-Denshi Inc. and The Shizuoka Cancer Center Research Institute jointly developed an A.I.-based Portable Odor detector/Identifier which analyzes malodorous components emitted from...
View ArticleClik here to view.
Foundation Medicine Advances Patient Access to Precision Medicine; Pursues...
CAMBRIDGE, Mass. Foundation Medicine, Inc. (NASDAQ:FMI) today announced that Chugai Pharmaceutical Co., Ltd. (TOKYO: 4519), one of Japan’s leading research-based pharmaceutical companies and a...
View ArticleClik here to view.
U.S. FDA Grants Priority Review for a Supplemental New Drug Application...
NEW YORK & TOKYO Pfizer Inc. (NYSE: PFE) and Astellas Pharma Inc. (TSE: 4503, President and CEO: Yoshihiko Hatanaka, “Astellas”) announced today that a supplemental New Drug Application (sNDA)...
View ArticleClik here to view.
牛津纳米孔科技有限公司宣布获得来自全球知名投资机构1亿英镑（约1.39亿美元）的投资
英国 , 牛津 牛津纳米孔科技有限公司（Oxford Nanopore Technologies...
View ArticleClik here to view.
Oxford Nanopore Announces £100 Million ($140M) Fundraising from Global Investors
OXFORD, England Oxford Nanopore Technologies Ltd, the company behind the only portable real-time DNA/RNA sequencer, MinION, has raised £100M ($140M) in new investment. Funds were raised from global...
View ArticleClik here to view.
Takeda Announces Publication of Final Data from ICLUSIG® (ponatinib) Pivotal...
CAMBRIDGE, Mass. & OSAKA, Japan Takeda Pharmaceutical Company Limited (TSE: 4502) today announced that final data from the pivotal Phase 2 PACE clinical trial of ICLUSIG (ponatinib) in...
View ArticleClik here to view.
武田宣布发表ICLUSIG® (ponatinib)枢纽性2期PACE血液病试验的终局数据
马萨诸塞州剑桥和日本大阪 (美国商业资讯) — 武田药品工业株式会社(TSE: 4502)今天宣布，《血液》杂志发表ICLUSIG (ponatinib)治疗难治性慢性粒细胞性白血病(CML)或费城染色体阳性急性淋巴细胞性白血病(Ph+...
View ArticleClik here to view.
Seattle Genetics and Astellas Receive FDA Breakthrough Therapy Designation...
BOTHELL, Wash. & TOKYO Seattle Genetics, Inc. (NASDAQ: SGEN) and Astellas Pharma Inc. (TSE: 4503, President and CEO: Yoshihiko Hatanaka, “Astellas”) today announced that the U.S. Food and Drug...
View ArticleClik here to view.
武田薬品がアイクルシグ（ポナチニブ）のピボタル第2相PACE試験から得た最終データのブラッド誌掲載を発表
米マサチューセッツ州ケンブリッジ & 大阪 （ビジネスワイヤ） — 武田薬品工業株式会社(TSE: 4502)は本日、難治性の慢性骨髄性白血病（CML）またはフィラデルフィア染色体陽性急性リンパ芽球性白血病（Ph+...
View ArticleClik here to view.
Toshiba Heavy-Ion Therapy System Awarded by Yonsei University Health System
KAWASAKI, Japan Toshiba Energy Systems & Solutions Corporation (Toshiba ESS), a world leader in heavy-ion therapy system, in collaboration as a consortium with DK Medical Solutions, a Korean...
View ArticleClik here to view.
MaxiNovel Pharmaceuticals, Inc. Announces FDA Orphan Drug Designation for...
GUANGZHOU, China MaxiNovel Pharmaceuticals, Inc. announced today that the U.S. Food and Drug Administration (“FDA”) has granted MaxiNovel Orphan Drug Designation for MAX-40279 in the treatment of...
View ArticleClik here to view.
Cullgen Announces ALK PROTACs Publication by Its Co-founders in the European...
DOVER, Del. Cullgen Inc., a biopharmaceutical company focusing on developing new drugs using protein degradation technology today announced that the laboratories of its co-founders, Dr. Jian Jin and...
View Article